June 2, 2020 / 12:57 PM / a month ago

BRIEF-Idera Announces Preliminary Data From Illuminate-206 Trial For Treatment Of Micro-Satellite Stable Colorectal Cancer

June 2 (Reuters) - Idera Pharmaceuticals Inc:

* IDERA PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM AND PLANNED CONTINUATION OF THE ILLUMINATE-206 TRIAL FOR THE TREATMENT OF MICRO-SATELLITE STABLE COLORECTAL CANCER

* IDERA PHARMACEUTICALS - BASED ON DATA TO DATE, PLANS TO EXPAND STUDY TO FURTHER EVALUATE TRIPLET COMBINATION IN MSS-CRC

* IDERA PHARMACEUTICALS - ILLUMINATE-206 REGIMEN WAS GENERALLY WELL TOLERATED

* IDERA PHARMACEUTICALS - NO PATIENTS DISCONTINUED TREATMENT DUE TO ADVERSE EVENTS & NONE EXPERIENCED GRADE 4 OR 5 AES IN ILLUMINATE-206 TRIAL

* IDERA PHARMACEUTICALS - ENROLLMENT OF NEXT 10 PATIENTS IS TARGETED TO BEGIN IN Q4 OF 2020, WITH DATA ANTICIPATED IN Q2 OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below